DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Recruiting · NCT06964009 · Registry updated 2026-09-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian carcinoma, ovarian disorder | Recruiting | Phase 1 | 2026-09-11 | NCT06964009 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| American Society of Clinical Oncology | 17 |
| Dialectic Therapeutics, Inc | 1 |
| Elizabeth Stover, MD, PhD | 1 |
| United States Department of Defense | 319 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth Israel Deaconess Medical Center (BIDMC) | Boston | United States | 2 |
| Brigham and Women's Hospital | Boston | United States | 60 |
| Dana Farber Cancer Institute | Boston | United States | 133 |